Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
SAN CARLOS, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
NexImmune Proposes Terms For $75 Million IPO
01:18pm, Monday, 08'th Feb 2021
NexImmune Proposes Terms For $75 Million IPO
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
08:56am, Tuesday, 19'th Jan 2021
SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Iovance Biotherapeutics: Banking On Robust Data
09:50am, Monday, 28'th Dec 2020
Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, ar
Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
07:30am, Monday, 28'th Dec 2020
SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer
07:00am, Monday, 14'th Dec 2020
SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Iovance Biotherapeutics to Present at Upcoming Conferences in December
07:21am, Monday, 30'th Nov 2020
SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript
04:23am, Friday, 06'th Nov 2020
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript
Iovance Biotherapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5, 2020
07:00am, Friday, 30'th Oct 2020
SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
Iovance Biotherapeutics to Present at Upcoming Conferences in November
07:45am, Wednesday, 28'th Oct 2020
SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou
Despite Setback, Iovance's Lifileucel Remains A Multibillion Dollar Prospect
01:24pm, Tuesday, 27'th Oct 2020
Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a
Advances in treatment are driving the decline in lung cancer deaths - STAT
04:52pm, Thursday, 13'th Aug 2020
That fewer Americans smoke tobacco has led to a significant decline in lung cancer deaths. Advances in treatment are also a major contributor.
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus
03:22pm, Monday, 10'th Aug 2020
Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.
Seneca Biopharma (NASDAQ:SNCA) and Iovance Biotherapeutics (NASDAQ:IOVA) Financial Review
04:44am, Sunday, 09'th Aug 2020
Seneca Biopharma (NASDAQ:SNCA) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of th
